IDEAYA Biosciences (IDYA) Competitors

$28.32 +0.11 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$28.19 -0.13 (-0.47%)

As of 06:26 PM Eastern

IDYA vs. ABVX, CYTK, PRAX, KRYS, and PCVX

Should you buy IDEAYA Biosciences stock or one of its competitors? MarketBeat compares IDEAYA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IDEAYA Biosciences include Abivax (ABVX), Cytokinetics (CYTK), Praxis Precision Medicines (PRAX), Krystal Biotech (KRYS), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does IDEAYA Biosciences compare to Abivax?

Abivax (NASDAQ:ABVX) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Abivax currently has a consensus price target of $137.15, indicating a potential upside of 20.79%. IDEAYA Biosciences has a consensus price target of $50.69, indicating a potential upside of 78.98%. Given IDEAYA Biosciences' higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

Abivax has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
IDEAYA Biosciences	$218.71M	11.38	-$113.70M	-$1.60	N/A

IDEAYA Biosciences' return on equity of -14.24% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

47.9% of Abivax shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Abivax and Abivax both had 2 articles in the media. IDEAYA Biosciences' average media sentiment score of 1.04 beat Abivax's score of 0.57 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IDEAYA Biosciences beats Abivax on 11 of the 14 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Cytokinetics?

IDEAYA Biosciences (NASDAQ:IDYA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

IDEAYA Biosciences has higher revenue and earnings than Cytokinetics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.38	-$113.70M	-$1.60	N/A
Cytokinetics	$88.04M	106.25	-$784.96M	-$6.84	N/A

IDEAYA Biosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

IDEAYA Biosciences has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 18 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 20 mentions for Cytokinetics and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.04 beat Cytokinetics' score of 0.46 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences currently has a consensus target price of $50.69, suggesting a potential upside of 78.98%. Cytokinetics has a consensus target price of $98.55, suggesting a potential upside of 31.09%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe IDEAYA Biosciences is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82

98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

IDEAYA Biosciences beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Praxis Precision Medicines?

IDEAYA Biosciences (NASDAQ:IDYA) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

IDEAYA Biosciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market.

IDEAYA Biosciences' return on equity of -14.24% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 16 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 18 mentions for Praxis Precision Medicines and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.04 beat Praxis Precision Medicines' score of 0.23 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.38	-$113.70M	-$1.60	N/A
Praxis Precision Medicines	$8.55M	1,045.19	-$303.27M	-$13.37	N/A

IDEAYA Biosciences currently has a consensus price target of $50.69, suggesting a potential upside of 78.98%. Praxis Precision Medicines has a consensus price target of $592.67, suggesting a potential upside of 84.90%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

Summary

IDEAYA Biosciences beats Praxis Precision Medicines on 10 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Krystal Biotech currently has a consensus price target of $324.11, indicating a potential upside of 11.09%. IDEAYA Biosciences has a consensus price target of $50.69, indicating a potential upside of 78.98%. Given IDEAYA Biosciences' higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

Krystal Biotech has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.10	$204.83M	$7.48	39.00
IDEAYA Biosciences	$218.71M	11.38	-$113.70M	-$1.60	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to IDEAYA Biosciences' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

In the previous week, Krystal Biotech had 5 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Krystal Biotech and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.04 beat Krystal Biotech's score of 0.87 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Summary

Krystal Biotech beats IDEAYA Biosciences on 12 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Vaxcyte?

IDEAYA Biosciences (NASDAQ:IDYA) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

IDEAYA Biosciences has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than Vaxcyte. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.38	-$113.70M	-$1.60	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

In the previous week, Vaxcyte had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 5 mentions for Vaxcyte and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.04 beat Vaxcyte's score of 0.70 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences' return on equity of -14.24% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Vaxcyte	N/A	-32.51%	-29.51%

IDEAYA Biosciences currently has a consensus target price of $50.69, indicating a potential upside of 78.98%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 77.54%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe IDEAYA Biosciences is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

IDEAYA Biosciences beats Vaxcyte on 11 of the 14 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.48B	$3.31B	$6.25B	$12.28B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-17.70	18.13	20.86	25.24
Price / Sales	11.38	277.94	549.88	74.17
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	2.43	6.57	9.67	6.63
Net Income	-$113.70M	$24.35M	$3.56B	$335.41M
7 Day Performance	0.68%	-3.17%	-1.91%	-1.83%
1 Month Performance	-16.48%	-3.55%	-2.65%	-1.16%
1 Year Performance	58.92%	56.89%	31.17%	28.31%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	3.5654 of 5 stars	$28.32 +0.4%	$50.69 +79.0%	+58.3%	$2.48B	$218.71M	N/A	80	Positive News
ABVX Abivax	3.3059 of 5 stars	$126.54 +2.2%	$137.15 +8.4%	+1,805.7%	$9.81B	N/A	N/A	61	Upcoming Earnings
CYTK Cytokinetics	2.6602 of 5 stars	$74.84 -2.9%	$96.75 +29.3%	+144.7%	$9.58B	$88.04M	N/A	250	Analyst Forecast
PRAX Praxis Precision Medicines	3.3948 of 5 stars	$338.07 +1.4%	$590.78 +74.8%	+825.4%	$9.29B	$8.55M	N/A	110
KRYS Krystal Biotech	3.5043 of 5 stars	$289.04 +1.6%	$324.11 +12.1%	+134.5%	$8.39B	$389.13M	38.64	210	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. ABVX, CYTK, PRAX, KRYS, and PCVX

How does IDEAYA Biosciences compare to Abivax?

Summary

How does IDEAYA Biosciences compare to Cytokinetics?

Summary

How does IDEAYA Biosciences compare to Praxis Precision Medicines?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Summary

How does IDEAYA Biosciences compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. ABVX, CYTK, PRAX, KRYS, and PCVX

How does IDEAYA Biosciences compare to Abivax?

Do analysts rate ABVX or IDYA?

Which has more volatility & risk, ABVX or IDYA?

Which has stronger valuation and earnings, ABVX or IDYA?

Is ABVX or IDYA more profitable?

Do insiders & institutionals hold more shares of ABVX or IDYA?

Does the media prefer ABVX or IDYA?

Summary

How does IDEAYA Biosciences compare to Cytokinetics?

Which has preferable earnings & valuation, IDYA or CYTK?

Which has more volatility and risk, IDYA or CYTK?

Is IDYA or CYTK more profitable?

Does the media refer more to IDYA or CYTK?

Do analysts rate IDYA or CYTK?

Do insiders and institutionals hold more shares of IDYA or CYTK?

Summary

How does IDEAYA Biosciences compare to Praxis Precision Medicines?

Which has more risk and volatility, IDYA or PRAX?

Is IDYA or PRAX more profitable?

Do insiders & institutionals have more ownership in IDYA or PRAX?

Does the media refer more to IDYA or PRAX?

Which has preferable earnings and valuation, IDYA or PRAX?

Do analysts prefer IDYA or PRAX?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Do analysts recommend KRYS or IDYA?

Which has higher valuation & earnings, KRYS or IDYA?

Do insiders and institutionals believe in KRYS or IDYA?

Is KRYS or IDYA more profitable?

Does the media prefer KRYS or IDYA?

Which has more risk and volatility, KRYS or IDYA?

Summary

How does IDEAYA Biosciences compare to Vaxcyte?

Which has more risk and volatility, IDYA or PCVX?

Which has higher valuation and earnings, IDYA or PCVX?

Does the media refer more to IDYA or PCVX?

Is IDYA or PCVX more profitable?

Do analysts prefer IDYA or PCVX?

Do institutionals & insiders believe in IDYA or PCVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools